Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    3(100%)

    Phase Distribution

    Phase 1/2
    1
    33%
    Phase 1
    1
    33%

    Phase Distribution

    1

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    Phase 1Safety & dosage
    1(50.0%)
    Phase 1/2Combined phases
    1(50.0%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    3

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(3)

    Detailed Status

    Recruiting2
    Active, not recruiting1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    3
    Success Rate
    N/A
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 11 (50.0%)
    Phase 1/21 (50.0%)

    Trials by Status

    active_not_recruiting133%
    recruiting267%

    Recent Activity

    3 active trials
    Showing 3 of 3
    recruitingphase_1

    A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

    NCT05911217
    recruiting

    To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

    NCT07179484
    active_not_recruitingphase_1_2

    Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

    NCT04581473

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT05911217Phase 1

    A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

    Recruiting
    NCT07179484

    To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

    Recruiting
    NCT04581473Phase 1/2

    Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

    Active Not Recruiting

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3